DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 990 filers reported holding DANAHER CORPORATION in Q3 2015. The put-call ratio across all filers is 0.69 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $95,230,207 | +381.5% | 383,838 | +365.8% | 0.03% | +342.9% |
| Q2 2023 | $19,778,880 | +178.7% | 82,412 | +192.7% | 0.01% | +133.3% |
| Q1 2023 | $7,095,934 | -15.4% | 28,154 | -10.9% | 0.00% | -25.0% |
| Q4 2022 | $8,384,087 | -65.5% | 31,588 | -66.4% | 0.00% | -63.6% |
| Q3 2022 | $24,267,000 | +689.9% | 93,951 | +675.4% | 0.01% | +1000.0% |
| Q2 2022 | $3,072,000 | -98.3% | 12,116 | -98.1% | 0.00% | -98.3% |
| Q1 2022 | $183,059,000 | +4.7% | 624,071 | +17.4% | 0.06% | +3.5% |
| Q4 2021 | $174,822,000 | -18.5% | 531,358 | -24.5% | 0.06% | -25.0% |
| Q3 2021 | $214,390,000 | +68.0% | 704,212 | +48.1% | 0.08% | +52.0% |
| Q2 2021 | $127,594,000 | +82.6% | 475,460 | +53.2% | 0.05% | +42.9% |
| Q1 2021 | $69,862,000 | +141.5% | 310,386 | +138.4% | 0.04% | +133.3% |
| Q4 2020 | $28,927,000 | +60.6% | 130,222 | +55.7% | 0.02% | +36.4% |
| Q3 2020 | $18,016,000 | -61.2% | 83,663 | -68.1% | 0.01% | -68.6% |
| Q2 2020 | $46,435,000 | +20.9% | 262,596 | -5.3% | 0.04% | -7.9% |
| Q1 2020 | $38,393,000 | +227.6% | 277,392 | +263.3% | 0.04% | +123.5% |
| Q4 2019 | $11,719,000 | +220.9% | 76,359 | +202.0% | 0.02% | +183.3% |
| Q3 2019 | $3,652,000 | -75.8% | 25,286 | -76.0% | 0.01% | -77.8% |
| Q2 2019 | $15,078,000 | +34.5% | 105,498 | +24.3% | 0.03% | +50.0% |
| Q1 2019 | $11,209,000 | +320.9% | 84,906 | +228.8% | 0.02% | +260.0% |
| Q4 2018 | $2,663,000 | -30.0% | 25,822 | -26.3% | 0.01% | -28.6% |
| Q3 2018 | $3,807,000 | -2.6% | 35,037 | -11.5% | 0.01% | -22.2% |
| Q2 2018 | $3,908,000 | -21.6% | 39,602 | -22.2% | 0.01% | -30.8% |
| Q1 2018 | $4,983,000 | -52.8% | 50,894 | -55.3% | 0.01% | -56.7% |
| Q4 2017 | $10,566,000 | +301.3% | 113,838 | +271.0% | 0.03% | +233.3% |
| Q3 2017 | $2,633,000 | +76.7% | 30,684 | +73.8% | 0.01% | +80.0% |
| Q2 2017 | $1,490,000 | +119.8% | 17,654 | +122.7% | 0.01% | +66.7% |
| Q1 2017 | $678,000 | +7.4% | 7,926 | -2.1% | 0.00% | 0.0% |
| Q4 2016 | $631,000 | -59.2% | 8,100 | -58.9% | 0.00% | -57.1% |
| Q3 2016 | $1,547,000 | -35.6% | 19,731 | -17.1% | 0.01% | -36.4% |
| Q2 2016 | $2,404,000 | -6.4% | 23,801 | -12.1% | 0.01% | -26.7% |
| Q1 2016 | $2,568,000 | -41.2% | 27,068 | -42.4% | 0.02% | -44.4% |
| Q4 2015 | $4,365,000 | +257.5% | 47,000 | +227.9% | 0.03% | +285.7% |
| Q3 2015 | $1,221,000 | -32.5% | 14,334 | -32.7% | 0.01% | -50.0% |
| Q1 2015 | $1,808,000 | +169.9% | 21,294 | +172.3% | 0.01% | +180.0% |
| Q4 2014 | $670,000 | -28.6% | 7,820 | -37.5% | 0.01% | -50.0% |
| Q1 2014 | $939,000 | – | 12,519 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |